Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in Type 1 and Type 2 Diabetes

Overview

About this study

The purpose of this study is determine the effect of β-cell function and glycemic control on islet GLP-1.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age range of 25-65 years
  • Type 1 or type 2 diabete
  • Reside within a 100-mile radius of the Mayo Clinic
  • Weight-stable, defined as a <3% change in body weight over the preceding 2 months (by history).

Exclusion Criteria :

  • Age < 25 or > 70 years.
  • HbA1c ³ 10.0%
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Prior use of GLP-1 receptor agonists in the previous year.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/16/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Contact us for the latest status

Contact information:

Jeanette Laugen

(507) 255-8110

Laugen.Jeanette@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20582093

Mayo Clinic Footer